Inovio Pharmaceuticals
INO
100 hedge funds and large institutions have $54.6M invested in Inovio Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 19 increasing their positions, 23 reducing their positions, and 15 closing their positions.
138% more call options, than puts
Call options by funds: $1.12M | Put options by funds: $469K
7% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 15
5% less capital invested
Capital invested by funds: $57.5M → $54.6M (-$2.87M)
2% less funds holding
Funds holding: 102 → 100 (-2)
2.68% less ownership
Funds ownership: 48.07% → 45.4% (-2.7%)
17% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EP
Eversept Partners
New York
|
+$1.7M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$471K |
| 3 |
GC
GMT Capital
Atlanta,
Georgia
|
+$208K |
| 4 |
Renaissance Technologies
New York
|
+$149K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$130K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.88M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$835K |
| 3 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$388K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$321K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$319K |
INO Hedge Fund Activity: Q1 2026 in Review
100 of the 8,173 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q1 2026, worth a combined $54.6M — down 5% from $57.5M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new INO positions and 15 closed out — a net gain of 1 holder — while 19 added to existing stakes and 23 trimmed.
The largest buyer was Eversept Partners, opening a new position worth an estimated $1.7M. The largest seller was Adage Capital Partners, cutting an estimated $2.88M.
- 100 institutional investors held Inovio Pharmaceuticals (INO) as of Q1 2026, down from 102 in Q4 2025.
- Funds reported $54.6M of Inovio Pharmaceuticals stock for Q1 2026, down 5% quarter-over-quarter.
- 16 funds opened new Inovio Pharmaceuticals positions in Q1 2026 and 15 closed out, a net change of +1 holder.
- The largest Inovio Pharmaceuticals buyer in Q1 2026 was Eversept Partners, an estimated $1.7M added.
- The largest Inovio Pharmaceuticals seller in Q1 2026 was Adage Capital Partners, an estimated $2.88M sold.
Based on aggregated 13F filings for Q1 2026.